Our Science – Kreitman Website
Robert J. Kreitman, M.D.
| Treatment of early hairy cell leukemia with cladribine and rituixmab - For patients with previously untreated hairy cell, or once-relapsed.|
| Phase II trial of LMB-2 in hairy cell leukemia - Multiply relapsed hairy cell, unable to receive HA22|
| HA22 recombinant immunotoxin for relapsed hairy cell leukemia - For patients with multiply relapsed hairy cell leukemia and no prior recombinant immunotoxin|
| Phase II trial of LMB-2 after fludarabine and cyclophosphamide for adult T-cell leukemia - For patients with adult T-cell leukemia to target the ATL cells, using FC chemotherapy to prevent antibodies and improve the chance for complete remission|
| Randomized trial of rituximab with either bendamustine or pentostatin for hairy cell leukemia - Patients who have had multiple prior treatments for HCL|
| Phase I/II trial of HA22 for chronic lymphocytic leukemia and non-Hodgkin's lymphoma - A non-chemotherapy option for patients with CLL and NHL which has been previously treated with chemotherapy, including rituximab.|
This page was last updated on 9/5/2011.